Aquestive Therapeutics Reports Third Quarter 2023 Financial

Reiterates commencement of pivotal pharmacokinetic (PK) study for Anaphylm™ (epinephrine) Sublingual Film expected in fourth quarter 2023 with topline data...

Related Keywords

Daniel Barber , Stephanie Carrington , Indivior Suboxone , Aquestive Therapeutics Inc , Nasdaq , Development Expense , Linkedin , Drug Administration , Exchange Commission , Senior Secured Notes Of The Company , Sublingual Film , Chief Executive Officer , New Drug Application , Buccal Film , Rectal Gel , Riluzole Oral Film , Lennox Gastaut Syndrome , Attention Deficit Hyperactivity Disorder , Senior Secured Notes , Note Holders , Conference Call , Private Securities Litigation Reform Act , Quarterly Reports , Current Reports , Aquestive Therapeutics , Consolidated Statements , Comprehensive Income , Nasdaq Aqst , Nc ,